Stem Cell Stocks 2013 - Stem Cell Stocks to Buy 2013 - Top Stem Cell Stock Picks

Investing in Stocks
Stock Picks
Today's Biggest Stock Gainers
Today's Biggest Stock Losers
Best Performing Stocks
2015 Stock Gainers
2015 Penny Stock Gainers
Stocks 2015
Top Stocks 2015
Top Penny Stocks 2015
IPO's in 2015
Stocks to Buy 2015
Oil Stocks to Buy 2015
Best Solar Stocks 2015
Top Gold Stocks 2015
Top Silver Stocks 2015
Dividend Stocks 2015
Bank Stocks 2015
Tech Stocks 2015
Cramer Stock Picks 2015
Icahn Stock Picks 2015
Top 10 Stocks 2015
Top 10 Penny Stocks
Best Coffee Stocks 2015
Best China Stocks 2015
Best Marijuana Stocks 2015
Best Ebola Stocks 2015
Hot OTC Stocks
Long Term Stocks
Dividend Stocks
Penny Stocks to Buy
Top Stocks 2016
Top Penny Stocks 2016
How to Day Trade
Stock Trading Rules
Pink Sheets Stocks
OTC Stocks
Site Map
Contact Us

counter create hit

Top Stem Cell Stocks 2013 - Stem Cell Stock Picks 2013 - Stem Cell Stocks to Buy

What are the best stem cell stocks to buy for 2013?  There is a full list of stem cell stocks to buy in 2013 based on clinic trial data.  This is an exciting time for stem cell stocks due to the advancement in clinical trials and many new discoveries.  While almost all of the stem cell stock picks lose money, there is a constant flow of money moving into these companies which is sparking innovation.  Below is a list of the top stem cell stocks to buy in 2012/2013.  These are my top stem stock picks and are stocks I trade personally in my stock picks group.

Top Stem Cell Stocks 2012/2013 - Pluristem Therapeutics, Inc. (PSTI) - Pluristem Therapeutics, Inc. (PSTI) is the top stem cell stock right now in 2012 as the company continues to release positive news on clinical trials.  Pluristem Therapeutics, Inc. (PSTI) stock is currently trading at $4.25, Up 68% in 2012.  Please note that PSTI is a stock to buy for the future as they will need a lot of capital to survive.  This small cap biotech company might not be able to bring a drug to market until 2019 or 2020.

Pluristem Therapeutics, Inc. (PSTI) a bio-therapeutic company, engages in the research, development, and commercialization of standardized cell therapy products for the treatment of life threatening diseases. The company’s products are derived from human placenta, a non-controversial, non-embryonic, adult cell source. Its Placental adherent stromal cells are grown in the company's proprietary PluriX three-dimensional process that allows cells to grow in a natural environment. The company provides PLX-PAD that has completed Phase I clinical trials for people suffering from peripheral artery disease. It also offers various product candidates for diabetic foot ulcers, adjuvant hip replacement surgery, athletic injuries, inflammatory bowel disease, multiple sclerosis, neuropathic pain, ischemic stroke, adjuvant for UCB transplantation, and radiation exposure.

Top Stocks 2014 - Click Here

Best Stem Cell Stocks 2013 - StemCells Inc. (STEM) - StemCells Inc. (STEM) is a stock I have been trading during the summer of 2012 in the stock picks group.  STEM is a $2 stock that has doubled over the past three months due to several $20 million grants and positive clinical trial data.  I feel that if STEM continues to report good news, this stem cell stock is a great buy.  StemCells, Inc. Awarded $20 Million From the California Institute for Regenerative Medicine for Alzheimer's Disease Program. 

StemCells (STEM) Price Target 2013 - $4 - STEM is a great stem cells stock to buy if you are looking for a high risk penny stock.

StemCells, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of stem cell therapeutics, and related tools and technologies for academia and industry. It develops cell-based therapeutics for the central nervous system and liver. The company’s product candidate HuCNS-SC cells has completed a Phase I clinical trial for the treatment of infantile and late infantile neuronal ceroid lipofuscinosis, a neurodegenerative disorder of the brain; and completed a Phase I clinical trial for the treatment of Pelizeaus-Merzbacher disease, a fatal myelination disorder in the brain. It also engages in developing HuCNS-SC cells, which are in Phase I/II clinical trial for the treatment of chronic spinal cord injury; and HuCNS-SC cells that are in Phase I/II clinical trial for the treatment of dry age-related macular degeneration. In addition, the company identifies and develops human liver engrafting cells for a range of liver diseases; and is involved in developing and commercializing applications of its technologies to enable stem cell-based research. 

Stem Cell Stock Picks 2013 - More:

Geron (GERN) - Treating cancer with Stem Cells
Osiris Therapeutics, Inc. (OSIR) - Treating Crohn's Disease, Osteoarthritis, Diabetes with Stem Cells
Aastrom Biosciences, Inc. (ASTM) - Stem Cells Penny Stock

My Stock Forum
Join Today!